Symbyax

Premature Ejaculation, Cataplexy, Bulimia Nervosa + 11 more
Treatment
6 FDA approvals
20 Active Studies for Symbyax

What is Symbyax

FluoxetineThe Generic name of this drug
Treatment SummaryOlanzapine is an antipsychotic drug used to treat mental health conditions. It was developed in the 1990s and is classified as a second-generation antipsychotic. It works similarly to clozapine but with a few differences. It was approved for use in the United States in 1996 and is manufactured by Eli Lilly. Olanzapine is known for its effectiveness and low risk of side effects, as well as its low risk of drug-drug interactions.
Prozacis the brand name
image of different drug pills on a surface
Symbyax Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Prozac
Fluoxetine
1987
490

Approved as Treatment by the FDA

Fluoxetine, also known as Prozac, is approved by the FDA for 6 uses such as Bipolar 1 Disorder and Premenstrual Dysphoric Disorder (PMDD) .
Bipolar 1 Disorder
Used to treat Bipolar 1 Disorder in combination with Olanzapine
Premenstrual Dysphoric Disorder (PMDD)
Major depressive disorder, recurrent episode
Used to treat Major depressive disorder, recurrent episode in combination with Olanzapine
Bipolar Disorder
Used to treat Bipolar 1 Disorder in combination with Olanzapine
Depression
Used to treat Depression in combination with Olanzapine
Unipolar Depression
Used to treat Major depressive disorder, recurrent episode in combination with Olanzapine

Effectiveness

How Symbyax Affects PatientsOlanzapine is used to treat symptoms of schizophrenia and bipolar disorder in adults, and manic or mixed episodes in adolescents. It works by blocking dopamine and serotonin receptors in the brain, which can help reduce hallucinations, delusions, and other disorganized thoughts and behaviors. It can also help decrease feelings of anhedonia, flat affect, alogia, avolition, and poor attention. Olanzapine has also been shown to reduce chemo-induced nausea and vomiting. In many studies, a complete response was reported in 84% of those taking the drug, with control of vomiting over 80%.
How Symbyax works in the bodyOlanzapine works by blocking certain receptors in the brain. It blocks dopamine, serotonin, and other receptors. The key action is blocking dopamine from binding to receptors in the mesolimbic pathway. This helps dampen nerve firing to reduce the symptoms of mental illnesses. Olanzapine also acts on serotonin receptors in the frontal cortex to help reduce the side effects.

When to interrupt dosage

The prescribed measure of Symbyax is contingent upon the diagnosed condition, including Schizophrenia, Bipolar Disorder and Delirium. The dosage amount shifts as per the administration technique (e.g. Kit - Intramuscular or Tablet, film coated - Oral) demonstrated in the table below.
Condition
Dosage
Administration
Premature Ejaculation
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Cataplexy
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Bulimia Nervosa
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Anorexia Nervosa
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Panic Disorder
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Alcoholism
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Unipolar Depression
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
moderate to severe symptoms
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Depression
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Myoclonus
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Bipolar Disorder
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
maintenance therapy
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Obsessive-Compulsive Disorder
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral
Depression
, 90.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 60.0 mg, 20.0 mg/mL, 15.0 mg
, Capsule, delayed release, Capsule, delayed release - Oral, Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit, Solution, Solution - Oral, Liquid, Liquid - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

Symbyax Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Symbyax.
Common Symbyax Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Fluoxetine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Fluoxetine.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Fluoxetine.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Fluoxetine.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Fluoxetine.
Symbyax Toxicity & Overdose RiskSymptoms of olanzapine overdose may include drowsiness, dilated pupils, difficulty breathing, low blood pressure, muscle twitching, and anticholinergic effects. Children may experience more serious side effects. The maximum registered dosage of olanzapine in clinical trials was 300mg and can cause drowsiness and slurred speech. Reported post-marketing symptoms include agitation, trouble speaking, fast heartbeat, and reduced consciousness. One case of death from overdosage occurred after ingesting 450mg of olanzapine. In the event of an overdose, treating the patient with oxygen, cleaning out the stomach
image of a doctor in a lab doing drug, clinical research

Symbyax Novel Uses: Which Conditions Have a Clinical Trial Featuring Symbyax?

578 active clinical trials are in progress to investigate the potential of Symbyax to ameliorate Schizophrenia, Post Traumatic Stress Disorder and Delusional Parasitosis.
Condition
Clinical Trials
Trial Phases
Depression
212 Actively Recruiting
Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1, Early Phase 1
Bipolar Disorder
0 Actively Recruiting
Unipolar Depression
47 Actively Recruiting
Not Applicable, Phase 4, Early Phase 1, Phase 3, Phase 2, Phase 1
Bulimia Nervosa
0 Actively Recruiting
Alcoholism
7 Actively Recruiting
Not Applicable, Phase 2, Phase 3
Anorexia Nervosa
0 Actively Recruiting
moderate to severe symptoms
0 Actively Recruiting
Depression
302 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3
Panic Disorder
0 Actively Recruiting
Obsessive-Compulsive Disorder
66 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1
maintenance therapy
0 Actively Recruiting
Myoclonus
1 Actively Recruiting
Not Applicable
Cataplexy
0 Actively Recruiting
Premature Ejaculation
0 Actively Recruiting

Symbyax Reviews: What are patients saying about Symbyax?

5Patient Review
2/17/2014
Symbyax for Major Depressive Disorder
When I started this medication, I felt very tired and dizzy. However, after about a month my body adjusted and I felt great—like a whole new person! My anxiety decreased so much that I no longer need to take anxiety medication during the day; only at night. The only side effect is some hand trembling, which hopefully won't get worse. Overall, I love this medicine because it changed my life and lifted my mood from severe depression.
5Patient Review
7/3/2013
Symbyax for Bipolar Depression
I sleep so much better now, and I even feel a little more functional during the day. That being said, I still struggle with depression and anger. It would be nice to just feel normal for once - not nauseous and anxious all the time.
5Patient Review
6/25/2013
Symbyax for Major Depressive Disorder
I wasn't warned about the potential for excessive weight gain until after I had put on about 70 pounds. If anyone has successfully tapered off this medication, I would love to hear from you about your experience.
5Patient Review
11/9/2014
Symbyax for Bipolar Depression
Symbyax has been a huge help for me in evening out my moods and reducing depression. The only downside is that it can make you sleepy, but since I take it at night that's not too big of a deal.
4.7Patient Review
6/2/2011
Symbyax for Major Depressive Disorder
4.3Patient Review
6/30/2011
Symbyax for Major Depressive Disorder
4.3Patient Review
8/11/2011
Symbyax for Bipolar Depression
4Patient Review
7/11/2011
Symbyax for Major Depressive Disorder
3.7Patient Review
10/3/2016
Symbyax for Bipolar Depression
This combination is an old school approach to stability. For myself, improving sleep and reducing the risk of crashes are the biggest indicators of continuing stability.
3.7Patient Review
10/1/2012
Symbyax for Bipolar Depression
I'm not sure.
3.3Patient Review
6/9/2011
Symbyax for Bipolar Depression
3Patient Review
11/4/2011
Symbyax for Bipolar Depression
My boyfriend started this medication a week ago at a dosage of 3/25mg. He is supposed to finish his supply and then increase the dosage. I have noticed a slight difference in his mood swings, but nothing significant. Does anyone know how long it will take for the full effects to be seen?
2.3Patient Review
8/20/2015
Symbyax for Bipolar Depression
I had an unfortunate reaction to the Zoloft in this medication. I felt itchy and irritable all over my body, and also found myself feeling very agitated and listless. I ended up having to go to a psychiatric triage center where they told me I was having an allergic reaction and needed to stop taking the medication immediately.
2Patient Review
5/19/2011
Symbyax for Major Depressive Disorder
1Patient Review
6/27/2011
Symbyax for Bipolar Depression
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about symbyax

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Symbyax help with anxiety?

"In general, I have found symbyax to be helpful in managing my depression and anxiety. It has also helped me to sleep better."

Answered by AI

What is Symbyax used to treat?

"This medication is used to treat depression which is associated with bipolar disorder, as well as depression that has not responded to other medications. Some of the ways in which this medication can improve your condition are by helping you sleep, improve your mood, improve your concentration, and decrease nervousness."

Answered by AI

Is Symbyax a Prozac?

"Symbyax is a prescription drug that combines the antidepressant Prozac and antipsychotic Zyprexa. It is primarily used to treat bipolar depression in adults and children, but it can also be used to treat adults with depression who are resistant to other antidepressants."

Answered by AI

Does Symbyax cause weight gain?

"The medication Symbyax is a combination of the antidepressant fluoxetine and the antipsychotic olanzapine. It is associated with weight gain."

Answered by AI

Clinical Trials for Symbyax

Image of St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Psychotherapy for Depression

18 - 65
Female
Hamilton, Canada
The RESPOND trial explores the link between early life adversity and later life depressive symptoms. The investigators have designed a new psychological therapy tailored to address the symptoms that can be caused by difficult experiences in early life. These symptoms include low mood, emotional dysregulation, and distressing thoughts and beliefs related to difficult or traumatic experiences. The investigators would like to see if this new therapy helps people feel better. The investigators are also studying the biological changes that can occur as a result of early life adversity, and how this therapy may influence those changes. To do this, The investigators ask questions about participants' physical and mental health and take blood samples.
Recruiting
Has No Placebo
St. Joseph's Healthcare HamiltonSheryl Green, PhD
Image of University of Rochester Medical Center in Rochester, United States.

Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression

18+
All Sexes
Rochester, NY
The goal of this clinical trial is to understand the effect of ketamine on the brain in people with treatment-resistant depression (TRD). TRD occurs in around a third of people with depression and leads to higher suicide rates compared to those with major depressive disorder. A desperate need for a rapid acting antidepressant drug (RAAD) is needed to help improve quality of life for people with TRD. Ketamine has been shown to be a RAAD, and esketamine (a form of ketamine) was approved by the FDA to treat TRD. Ketamine has been known to cause dissociative experiences, that can lead to an increase in the "Openness to Experience" personality trait and psychological flexibility that occurs at "peak experience". This has been shown to improve mental health conditions and lower suicide risk. Our study aims to further understand if there is a connection between this new change of mind and changes in brain activity. Ketamine has been shown to improve brain plasticity as well, specifically in the frontolimbic region of the brain, an area associated with depression. We are analyzing the brain using functional magnetic resonance imaging (fMRI), a method used to measure brain activity. The frontolimbic region is also associated with cognitive flexibility and emotional processing, an important hurdle in treating TRD. Due to this, we are pairing the ketamine treatment with psychotherapy sessions, to guide the processing experience, which can lead to higher emotional flexibility. The main questions this study aims to answer are: * Are frontolimibic plasticity circuitry changes associated with openness to experience and peak experience? * Is it feasible to recruit and retain people through a two-month study? * Is the structure of the study effective for treating TRD? Participants will: * Visit the facilities 6-8 times * Complete 2 MRI brain scans * Complete 3-4 psychotherapy sessions * Receive 1-2 doses of ketamine * Complete online surveys between 3-4 visits
Phase 2
Waitlist Available
University of Rochester Medical Center
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA
The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical CenterScott Irwin, MD
Have you considered Symbyax clinical trials? We made a collection of clinical trials featuring Symbyax, we think they might fit your search criteria.Go to Trials
Image of Cohen and Associates in Sarasota, United States.

NRX-101 + TMS for Treatment Resistant Depression

18 - 80
All Sexes
Sarasota, FL
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an alternative. Repetitive transcranial magnetic stimulation (rTMS) and more recently, theta-burst stimulation (TBS), are the noninvasive brain stimulation modalities with the largest evidence base in MDD. Although efficacious, an unacceptable proportion of patients do not significantly improve, and several aspects of the TMS parameter space are under investigation to enhance clinical outcomes. DCS has been shown in a randomized trial of more than double the percent response and remission from traditional TMS. When the AMPA one day (ONE-D) TMS protocol was combined with DCS, the measured response rate was 87% at one week. This trial will compare response and remission at six weeks following Transcranial Magnetic Stimulation + D-cycloserine vs. TMS+placebo.
Phase 2 & 3
Waitlist Available
Cohen and AssociatesNeuroRx, Inc.
Have you considered Symbyax clinical trials? We made a collection of clinical trials featuring Symbyax, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL
This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.
Recruiting
Has No Placebo
Mayo Clinic in FloridaJuan C. Cardenas Rosales, MD
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL
The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.
Waitlist Available
Has No Placebo
Virtual/ No Physical FacilityCandice S Rasa, LCSW
Have you considered Symbyax clinical trials? We made a collection of clinical trials featuring Symbyax, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security